Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/ced/llad404 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Neoadjuvant or perioperative therapy for melanoma metastasis in clinical practice: an international survey.
Lancet Oncol
January 2025
Melanoma World Society, HERACLIN Institute for Data Management in Healthcare, Neuenhagen, Germany.
Age over 90 years is an unfavorable prognostic factor for resectable cutaneous squamous cell carcinoma.
J Dermatol
January 2025
Department of Dermato-Oncology, NHO Kagoshima Medical Center, Kagoshima, Japan.
The rapid aging of the population has led to an increase in the number of cutaneous squamous cell carcinoma (cSCC) cases among the older population. However, the characteristics of these cases remain unclear. In this study, we aimed to identify the problem by analyzing the clinical characteristics of patients with cSCC aged 90 years and over.
View Article and Find Full Text PDFFatal Spitz Melanoma With MAD1L1::BRAF Fusion: A Case Report and Literature Review.
J Cutan Pathol
December 2024
Drug Discovery and Development Division, Shizuoka Cancer Center Research Institute, Sunto, Japan.
Spitz melanoma is extremely rare, and only a few cases of distant metastases have been reported. Herein, we describe a case of Spitz melanoma with multiple distant metastases. A 37-year-old woman presented with a 5.
View Article and Find Full Text PDFAdvances in cancer treatments have significantly improved their effectiveness, yet access to first-line therapies remains limited. A 2017 survey revealed that over 25 % of metastatic melanoma patients in Europe lacked access to recommended therapies. To address this, the European Association of Dermato-Oncology and the European Melanoma Registry conducted a follow-up study on the registration and reimbursement of first-line treatments.
View Article and Find Full Text PDFWhen to stop immunotherapy for advanced melanoma: the emulated target trials.
EClinicalMedicine
December 2024
AP-HP Hotel-Dieu Hospital, Centre de Recherche épidémiologie et Statistiques (CRESS-UMR1153), Centre d'épidémiologie Clinique, Inserm / Université Paris Cité / AP-HP, Centre Virchow-Villermé, Centre Equator France, Paris, France.
Background: Immune checkpoint inhibitors (ICIs) have demonstrated their efficacy with a 7.5-year overall survival (OS) close to 50% for advanced stages. The design of clinical trials provides for treatment until progression or toxicity, or for a maximum duration of two years.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!